CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MRK

Gefapixant

Phase 3
MERCK (MRK)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

2

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Apr '27
MRKPhase 3

Placebo Phase 3 Est. Readout

Gefapixant
Apr 2027~
CT.gov
00%
Competitive Landscape

1 competitor in Chronic Cough

View Full Landscape
Drug Information

Target Indication

Chronic Cough

Clinical Trial

NCT04193202

Last updated: 12/16/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Gefzuris

Treatment of refractory or unexplained chronic cough.

View on EMA
EMA9/15/2023

Lyfnua

Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.